The company said, “These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target lowered to $43 from $50 at UBS
- Harmony Biosciences price target lowered to $36 from $54 at Deutsche Bank
- Harmony Biosciences price target lowered to $35 from $50 at Mizuho
- Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
- Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline Outlook